Annex 3 - A. Policy adoption, 2018

WHO region -treated nets Indoor residual spraying Chemoprevention Testing Treatment Country/area ITNs/LLINs ITNs/LLINs ITNs/LLINs ITNs/LLINs IRS is DDT is used IPTp is used Seasonal Patients of all RDTs are G6PD test is ACT for Pre-referral Single dose of Primaquine Directly are are distributed distributed recommended for IRS to prevent malaria ages should diagnosis is used recommended treatment of treatment primaquine is used for observed distributed distributed through through by malaria malaria chemo­ get diagnostic free of charge at community before P. falciparum with quinine or is used as radical treatment free of through EPI/well mass control during prevention test in the public level treatment with artemether IM gametocidal treatment of with charge ANC baby clinic campaigns programme pregnancy (SMC or sector primaquine or artesunate medicine for P. vivax cases primaquine is IPTc) is used for suppositories P. falciparum1 undertaken is used treatment of P. vivax cases

AFRICAN Algeria NA NA NA NA   NA NA –  –  NA –    Angola        NA          Benin            –       NA NA NA    NA          Burkina Faso                  Burundi        NA  *        Cabo Verde NA NA NA NA   NA NA                           Central African Republic        NA          Chad                  Comoros        NA          Congo        NA          Côte d’Ivoire        NA          Democratic Republic of the Congo        NA          Equatorial Guinea        NA                 NA           NA NA    NA NA                 NA          Gabon        NA          Gambia                  Ghana                  Guinea                  Guinea-Bissau                  Kenya        NA          Liberia        NA                 NA                 NA          Mali                  Mauritania                  Mayotte  – – – –  NA NA –  –   –           NA           NA NA     NA          Niger                  Nigeria                  Rwanda        NA          Sao Tome and Principe        NA          Senegal                  Sierra Leone        NA          NA       NA          South Sudan2        NA          Togo          *  –             NA          United Republic of Tanzania3 NA Mainland        NA          Zanzibar        NA                 NA                 NA         

AMERICAS Argentina NA      NA NA          Belize       NA NA          Bolivia (Plurinational State of)       NA NA     NA –    Brazil       NA NA          Colombia       NA NA         

114 WHO region Insecticide-treated mosquito nets Indoor residual spraying Chemoprevention Testing Treatment Country/area ITNs/LLINs ITNs/LLINs ITNs/LLINs ITNs/LLINs IRS is DDT is used IPTp is used Seasonal Patients of all Malaria RDTs are G6PD test is ACT for Pre-referral Single dose of Primaquine Directly are are distributed distributed recommended for IRS to prevent malaria ages should diagnosis is used recommended treatment of treatment primaquine is used for observed distributed distributed through through by malaria malaria chemo­ get diagnostic free of charge at community before P. falciparum with quinine or is used as radical treatment free of through EPI/well mass control during prevention test in the public level treatment with artemether IM gametocidal treatment of with charge ANC baby clinic campaigns programme pregnancy (SMC or sector primaquine or artesunate medicine for P. vivax cases primaquine is IPTc) is used for suppositories P. falciparum1 undertaken is used treatment of P. vivax cases

AFRICAN Algeria NA NA NA NA   NA NA –  –  NA –    Angola        NA          Benin            –      Botswana  NA NA NA    NA          Burkina Faso                  Burundi        NA  *        Cabo Verde NA NA NA NA   NA NA          Cameroon                  Central African Republic        NA          Chad                  Comoros        NA          Congo        NA          Côte d’Ivoire        NA          Democratic Republic of the Congo        NA          Equatorial Guinea        NA          Eritrea        NA          Eswatini  NA NA    NA NA          Ethiopia        NA          Gabon        NA          Gambia                  Ghana                  Guinea                  Guinea-Bissau                  Kenya        NA          Liberia        NA          Madagascar        NA          Malawi        NA          Mali                  Mauritania                  Mayotte  – – – –  NA NA –  –   –    Mozambique        NA          Namibia  NA NA     NA          Niger                  Nigeria                  Rwanda        NA          Sao Tome and Principe        NA          Senegal                  Sierra Leone        NA          South Africa NA       NA          South Sudan2        NA          Togo          *  –      Uganda        NA          United Republic of Tanzania3 NA Mainland        NA          Zanzibar        NA          Zambia        NA          Zimbabwe        NA         

AMERICAS Argentina NA      NA NA          Belize       NA NA          Bolivia (Plurinational State of)       NA NA     NA –    Brazil       NA NA          Colombia       NA NA          2019 REPORT MALARIA WORLD

115 Annex 3 - A. Policy adoption, 2018

WHO region Insecticide-treated mosquito nets Indoor residual spraying Chemoprevention Testing Treatment Country/area ITNs/LLINs ITNs/LLINs ITNs/LLINs ITNs/LLINs IRS is DDT is used IPTp is used Seasonal Patients of all Malaria RDTs are G6PD test is ACT for Pre-referral Single dose of Primaquine Directly are are distributed distributed recommended for IRS to prevent malaria ages should diagnosis is used recommended treatment of treatment primaquine is used for observed distributed distributed through through by malaria malaria chemo­ get diagnostic free of charge at community before P. falciparum with quinine or is used as radical treatment free of through EPI/well mass control during prevention test in the public level treatment with artemether IM gametocidal treatment of with charge ANC baby clinic campaigns programme pregnancy (SMC or sector primaquine or artesunate medicine for P. vivax cases primaquine is IPTc) is used for suppositories P. falciparum1 undertaken is used treatment of P. vivax cases

AMERICAS Costa Rica       NA NA          Dominican Republic       NA NA          Ecuador       NA NA          El Salvador       NA NA          French Guiana       NA NA     –     Guatemala       NA NA     –           NA NA          Haiti       NA NA     –     Honduras       NA NA          Mexico       NA NA          Nicaragua       NA NA          Panama       NA NA          Peru       NA NA          Suriname       NA NA          Venezuela (Bolivarian Republic of)       NA NA         

EASTERN MEDITERRANEAN Afghanistan       NA NA          Djibouti       NA NA          Iran (Islamic Republic of)       NA NA          Pakistan       NA NA          Saudi Arabia       NA NA          Somalia        NA                 NA          Yemen       NA NA         

SOUTH-EAST ASIA Bangladesh       NA NA          Bhutan       NA NA          Democratic People’s Republic of Korea       NA NA     NA           NA NA          Indonesia       NA NA                NA NA          Nepal       NA NA          Thailand       NA NA          Timor-Leste       NA NA         

WESTERN PACIFIC Cambodia       NA NA                NA NA          Lao People’s Democratic Republic       NA NA          Malaysia       NA NA                 NA          Philippines       NA NA          Republic of Korea       NA NA          Solomon Islands       NA NA          Vanuatu       NA NA          Viet Nam       NA NA         

ACT: -based combination therapy; ANC: antenatal care; DDT: dichloro-diphenyl-trichloroethane; EPI: Expanded Programme on ● = Policy adopted and implemented this year. Available data from the world malaria report data collection form provides evidence for Immunization; G6PD: glucose-6-phosphate dehydrogenase; IM: intramuscular; IPTc: intermittent preventive treatment in children; implementation. IPTp: intermittent preventive treatment in pregnancy; IRS: indoor residual spraying; ITN: insecticide-treated ; LLIN: long-lasting ● = Policy adopted but not implemented this year (2018) or no supportive available data reported to WHO. insecticidal net; RDT: rapid diagnostic test; SMC: seasonal malaria chemoprevention; WHO: World Health Organization.  = Policy not adopted. 1 Single dose of primaquine (0.75 mg base/kg) for countries in the WHO Region of the Americas. NA = Question not applicable. 2 In May 2013, South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, https://apps.who.int/gb/ebwha/pdf_files/ WHA66/A66_R21-en.pdf). – = Question not answered and there is no information from previous years. 3 Where national data for the United Republic of Tanzania are unavailable, refer to Mainland and Zanzibar. * Free for children and/or pregnant women only.

116 WHO region Insecticide-treated mosquito nets Indoor residual spraying Chemoprevention Testing Treatment Country/area ITNs/LLINs ITNs/LLINs ITNs/LLINs ITNs/LLINs IRS is DDT is used IPTp is used Seasonal Patients of all Malaria RDTs are G6PD test is ACT for Pre-referral Single dose of Primaquine Directly are are distributed distributed recommended for IRS to prevent malaria ages should diagnosis is used recommended treatment of treatment primaquine is used for observed distributed distributed through through by malaria malaria chemo­ get diagnostic free of charge at community before P. falciparum with quinine or is used as radical treatment free of through EPI/well mass control during prevention test in the public level treatment with artemether IM gametocidal treatment of with charge ANC baby clinic campaigns programme pregnancy (SMC or sector primaquine or artesunate medicine for P. vivax cases primaquine is IPTc) is used for suppositories P. falciparum1 undertaken is used treatment of P. vivax cases

AMERICAS Costa Rica       NA NA          Dominican Republic       NA NA          Ecuador       NA NA          El Salvador       NA NA          French Guiana       NA NA     –     Guatemala       NA NA     –     Guyana       NA NA          Haiti       NA NA     –     Honduras       NA NA          Mexico       NA NA          Nicaragua       NA NA          Panama       NA NA          Peru       NA NA          Suriname       NA NA          Venezuela (Bolivarian Republic of)       NA NA         

EASTERN MEDITERRANEAN Afghanistan       NA NA          Djibouti       NA NA          Iran (Islamic Republic of)       NA NA          Pakistan       NA NA          Saudi Arabia       NA NA          Somalia        NA          Sudan        NA          Yemen       NA NA         

SOUTH-EAST ASIA Bangladesh       NA NA          Bhutan       NA NA          Democratic People’s Republic of Korea       NA NA     NA     India       NA NA          Indonesia       NA NA          Myanmar       NA NA          Nepal       NA NA          Thailand       NA NA          Timor-Leste       NA NA         

WESTERN PACIFIC Cambodia       NA NA          China       NA NA          Lao People’s Democratic Republic       NA NA          Malaysia       NA NA          Papua New Guinea        NA          Philippines       NA NA          Republic of Korea       NA NA          Solomon Islands       NA NA          Vanuatu       NA NA          Viet Nam       NA NA         

ACT: artemisinin-based combination therapy; ANC: antenatal care; DDT: dichloro-diphenyl-trichloroethane; EPI: Expanded Programme on ● = Policy adopted and implemented this year. Available data from the world malaria report data collection form provides evidence for Immunization; G6PD: glucose-6-phosphate dehydrogenase; IM: intramuscular; IPTc: intermittent preventive treatment in children; implementation. IPTp: intermittent preventive treatment in pregnancy; IRS: indoor residual spraying; ITN: insecticide-treated mosquito net; LLIN: long-lasting ● = Policy adopted but not implemented this year (2018) or no supportive available data reported to WHO. insecticidal net; RDT: rapid diagnostic test; SMC: seasonal malaria chemoprevention; WHO: World Health Organization.  = Policy not adopted. 1 Single dose of primaquine (0.75 mg base/kg) for countries in the WHO Region of the Americas. NA = Question not applicable. 2 In May 2013, South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, https://apps.who.int/gb/ebwha/pdf_files/ WHA66/A66_R21-en.pdf). – = Question not answered and there is no information from previous years. 3 * Free for children and/or pregnant women only.

Where national data for the United Republic of Tanzania are unavailable, refer to Mainland and Zanzibar. 2019 REPORT MALARIA WORLD

117